Detection of mutations from liquid biopsies - applications in cancer diagnostics

Speaker

Abstract

Cell-free DNA (cfDNA) is currently trending as a biomarker from liquid biopsy in several clinical applications, including oncology, organ and transplant medicine, and non-invasive prenatal testing (NIPT). Although considerably less invasive than tissue biopsy, due to the small amount of cfDNA found in circulation, there is a need to use efficient, highly sensitive extraction protocols coupled with robust and reliable technologies, such as next-generation sequencing (NGS) to detect these mutations.

Join our webinar hosted by Monika Seidel (PhD) to discuss the results of a study using Cytiva’s magnetic silica bead-based Sera-Xtracta™ Cell-Free DNA extraction kit* and targeted NGS for cancer biomarker detection in advanced non-small cell lung cancer (NSCLC) patient samples. The study demonstrates performance in a clinically relevant scenario where patient samples are analyzed for therapy stratification.

Learning objectives

  • Discuss the opportunities and challenges created with liquid biopsy samples
  • Review the impact of cell-free DNA extraction efficiency, yield and purity in downstream applications such as next-generation sequencing 
  • Demonstrate performance of Sera-Xtracta Cell-Free DNA Kit in a clinically relevant scenario where patient samples are analyzed for therapy stratification

Show Resources
Show Resources